H. Lundbeck A/S (OTCMKTS:HLUYY) Trading Down 0%

H. Lundbeck A/S (OTCMKTS:HLUYYGet Free Report)’s stock price traded down 0% during trading on Monday . The stock traded as low as $22.00 and last traded at $22.00. 7,500 shares were traded during trading, an increase of 327% from the average session volume of 1,758 shares. The stock had previously closed at $22.01.

Analyst Upgrades and Downgrades

A number of analysts have commented on HLUYY shares. Barclays downgraded H. Lundbeck A/S from an “overweight” rating to an “equal weight” rating in a research report on Tuesday, November 14th. Morgan Stanley assumed coverage on H. Lundbeck A/S in a research report on Tuesday, November 14th. They issued an “underweight” rating on the stock.

View Our Latest Report on H. Lundbeck A/S

H. Lundbeck A/S Stock Performance

The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.71 and a current ratio of 1.15. The stock has a market cap of $21.91 billion, a PE ratio of 25.00 and a beta of 0.68. The company’s 50 day simple moving average is $22.00 and its 200 day simple moving average is $22.00.

H. Lundbeck A/S Company Profile

(Get Free Report)

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.

Featured Articles

Receive News & Ratings for H. Lundbeck A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H. Lundbeck A/S and related companies with MarketBeat.com's FREE daily email newsletter.